ES2259845T3 - Uso de la daptomicina. - Google Patents

Uso de la daptomicina.

Info

Publication number
ES2259845T3
ES2259845T3 ES99949913T ES99949913T ES2259845T3 ES 2259845 T3 ES2259845 T3 ES 2259845T3 ES 99949913 T ES99949913 T ES 99949913T ES 99949913 T ES99949913 T ES 99949913T ES 2259845 T3 ES2259845 T3 ES 2259845T3
Authority
ES
Spain
Prior art keywords
dose
use according
daptomycin
once
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99949913T
Other languages
English (en)
Spanish (es)
Inventor
Frederick B. Oleson, Jr.
Francis P. Tally
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cubist Pharmaceuticals LLC
Original Assignee
Cubist Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26798675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2259845(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cubist Pharmaceuticals LLC filed Critical Cubist Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2259845T3 publication Critical patent/ES2259845T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
ES99949913T 1998-09-25 1999-09-24 Uso de la daptomicina. Expired - Lifetime ES2259845T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10182898P 1998-09-25 1998-09-25
US101828P 1998-09-25
US12575099P 1999-03-24 1999-03-24
US125750P 1999-03-24

Publications (1)

Publication Number Publication Date
ES2259845T3 true ES2259845T3 (es) 2006-10-16

Family

ID=26798675

Family Applications (2)

Application Number Title Priority Date Filing Date
ES06006697.4T Expired - Lifetime ES2603086T3 (es) 1998-09-25 1999-09-24 Uso de la daptomicina
ES99949913T Expired - Lifetime ES2259845T3 (es) 1998-09-25 1999-09-24 Uso de la daptomicina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES06006697.4T Expired - Lifetime ES2603086T3 (es) 1998-09-25 1999-09-24 Uso de la daptomicina

Country Status (26)

Country Link
US (2) US6468967B1 (enExample)
EP (2) EP1115417B1 (enExample)
JP (4) JP4184607B2 (enExample)
KR (2) KR20100051735A (enExample)
CN (2) CN1150029C (enExample)
AT (1) ATE322280T1 (enExample)
AU (1) AU764348B2 (enExample)
BR (1) BR9914051A (enExample)
CA (1) CA2344318C (enExample)
CY (3) CY1105556T1 (enExample)
DE (3) DE69930758T2 (enExample)
DK (2) DK1115417T3 (enExample)
ES (2) ES2603086T3 (enExample)
HK (1) HK1040363B (enExample)
HU (1) HU230656B1 (enExample)
IS (2) IS5890A (enExample)
LU (1) LU91254I2 (enExample)
NL (1) NL300232I2 (enExample)
NO (1) NO20011454L (enExample)
NZ (1) NZ510690A (enExample)
PL (2) PL203689B1 (enExample)
PT (2) PT1115417E (enExample)
RU (1) RU2363489C9 (enExample)
SI (2) SI1115417T1 (enExample)
TR (1) TR200100841T2 (enExample)
WO (1) WO2000018419A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1115417T1 (sl) 1998-09-25 2006-08-31 Cubist Pharm Inc Uporaba daptomicina
EP2298790A1 (en) 1999-12-15 2011-03-23 Cubist Pharmaceuticals, Inc. Daptomycin analogs as antibacterial agents
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
WO2002059145A1 (en) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
IL156394A0 (en) * 2000-12-18 2004-01-04 Cubist Pharm Inc Methods for preparing purified lipopeptides
EP1932853A1 (en) 2001-08-06 2008-06-18 Cubist Pharmaceutical Inc. Novel depsipeptides and process for preparing same
WO2004017925A2 (en) * 2002-08-23 2004-03-04 Genome Therapeutics Corporation Methods and reagents for preventing bacteremias
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20050277581A1 (en) * 2002-11-18 2005-12-15 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20050220862A1 (en) * 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US20080051326A1 (en) * 2004-11-12 2008-02-28 Alexander Dylan C Antiinfective Lipopeptides
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8524735B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US20070238630A1 (en) * 2006-03-29 2007-10-11 Phillips Douglas H Subcutaneous skin cleanser
EP2018864A1 (en) 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
EP2257159A4 (en) * 2008-03-04 2011-05-11 Elan Pharma Int Ltd STABLE LIQUID FORMULATIONS OF ACTIVE AGGREGATES AGAINST INFECTIONS, AND ADAPTED DOSING CHEMICALS OF ACTIVE AGGREGATES AGAINST INFECTIONS
CN104623633A (zh) 2008-07-17 2015-05-20 阿索尔达治疗公司 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂
DE102008046610A1 (de) * 2008-09-09 2010-03-11 Biomet Deutschland Gmbh Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt
CN102325532B (zh) 2008-10-07 2015-06-17 Mpex医药有限公司 用于减轻肺部炎症的左氧氟沙星吸入剂
KR20110091510A (ko) 2008-10-07 2011-08-11 엠펙스 파마슈티컬즈, 인코포레이티드 약동학 개선을 위한 에어로졸 플루오로퀴놀론 제형
US8809263B2 (en) * 2008-10-24 2014-08-19 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Anti-infective hydroxy-phenyl-benzoates and methods of use
RU2512396C2 (ru) 2008-12-22 2014-04-10 Кьюбист Фармасьютикалз, Инк. Новые противобактериальные средства для лечения грамположительных инфекций
NZ593892A (en) 2008-12-23 2013-11-29 Biosource Pharm Inc Antibiotic compositions for the treatment of gram negative infections
CA2767614C (en) * 2009-07-13 2019-01-15 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
US8450300B2 (en) * 2009-07-13 2013-05-28 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
ES2739979T3 (es) 2009-09-04 2020-02-05 Horizon Orphan Llc Uso de levofloxacino en aerosol para el tratamiento de la fibrosis quística
DK2504353T4 (da) 2009-11-23 2023-11-20 Cubist Pharmaceuticals Llc Lipopeptidsammensætninger og tilsvarende fremgangsmåder
US8247394B2 (en) 2010-06-02 2012-08-21 Cempra Pharmaceuticals Inc. Methods of treating urethritis and related infections using fusidic acid
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
US8461188B2 (en) 2011-10-20 2013-06-11 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
SG11201406123TA (en) 2012-03-30 2014-10-30 Cubist Pharm Inc 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE β-LACTAMASE INHIBITORS
US9655946B2 (en) * 2012-09-11 2017-05-23 Hospira Australia Pty Ltd. Daptomycin formulations and uses thereof
CN103006562B (zh) * 2013-01-21 2014-09-17 西南大学 达托霉素醇质体制剂
EP2969004A4 (en) 2013-03-15 2016-09-21 Melinta Therapeutics Inc METHOD FOR THE TREATMENT OF INFECTIONS IN OVERWEIGHT AND ADIPOSIVE PATIENTS USING ANTIBIOTICS
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
WO2017197291A1 (en) * 2016-05-13 2017-11-16 Spero Potentiator, Inc. Potentiation of antibiotic activity by a novel cationic peptide, spr741
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32455E (en) 1978-10-16 1987-07-07 Eli Lilly And Company A-21978 antibiotics and process for their production
USRE32333E (en) 1978-10-16 1987-01-20 Eli Lilly And Company A-21978 Antibiotics and process for their production
USRE32311E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4524135A (en) 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
USRE32310E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
US4885243A (en) 1984-10-09 1989-12-05 Eli Lilly And Company Process for producing A-21978C derivatives
US4800157A (en) 1985-09-09 1989-01-24 Eli Lilly And Company Process for producing the A-21978C antibiotics
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
US4874843A (en) 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
EP0386951A3 (en) * 1989-03-06 1992-05-20 Eli Lilly And Company An improved diluent formulation for daptomycin
FR2755857B1 (fr) * 1996-11-19 1998-12-24 Rhone Poulenc Rorer Sa Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
FR2772272B1 (fr) * 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
SI1115417T1 (sl) 1998-09-25 2006-08-31 Cubist Pharm Inc Uporaba daptomicina
US9393093B2 (en) 2008-02-18 2016-07-19 Covidien Lp Clip for implant deployment device

Also Published As

Publication number Publication date
CA2344318A1 (en) 2000-04-06
AU6268799A (en) 2000-04-17
AU764348B2 (en) 2003-08-14
BR9914051A (pt) 2001-06-19
US20020142948A1 (en) 2002-10-03
DE122006000049I1 (de) 2007-01-04
HU230656B1 (hu) 2017-06-28
RU2363489C9 (ru) 2010-03-20
DE69930758T2 (de) 2007-04-26
WO2000018419A3 (en) 2000-07-06
CN1530136A (zh) 2004-09-22
PL206091B1 (pl) 2010-06-30
SI1674107T1 (sl) 2017-01-31
DE122006000049I2 (de) 2007-11-08
EP1674107A3 (en) 2012-06-20
EP1674107A8 (en) 2006-10-04
EP1674107B1 (en) 2016-08-24
DK1115417T3 (da) 2006-07-31
HUP0103874A3 (en) 2002-09-30
JP4184607B2 (ja) 2008-11-19
EP1674107A2 (en) 2006-06-28
KR20010075327A (ko) 2001-08-09
TR200100841T2 (tr) 2002-01-21
CA2344318C (en) 2006-07-04
PL203689B1 (pl) 2009-11-30
JP2004339238A (ja) 2004-12-02
HK1040363B (en) 2007-01-26
ES2603086T3 (es) 2017-02-23
CN1348382A (zh) 2002-05-08
NZ510690A (en) 2002-10-25
CY1118334T1 (el) 2017-06-28
EP1115417A2 (en) 2001-07-18
PL348328A1 (en) 2002-05-20
NO20011454L (no) 2001-05-25
SI1115417T1 (sl) 2006-08-31
LU91254I2 (fr) 2006-08-28
KR20100051735A (ko) 2010-05-17
CN1150029C (zh) 2004-05-19
HUP0103874A2 (hu) 2002-02-28
JP2006335773A (ja) 2006-12-14
EP1674107B8 (en) 2017-01-25
RU2363489C2 (ru) 2009-08-10
US6852689B2 (en) 2005-02-08
NO20011454D0 (no) 2001-03-22
RU2004106569A (ru) 2005-08-10
JP2003321389A (ja) 2003-11-11
NL300232I2 (nl) 2007-01-02
CY1105556T1 (el) 2010-07-28
IS5890A (is) 2001-03-14
DE69930758D1 (de) 2006-05-18
CY2006003I1 (el) 2009-11-04
JP2002525335A (ja) 2002-08-13
CY2006003I2 (el) 2009-11-04
DK1674107T3 (en) 2016-12-19
WO2000018419A2 (en) 2000-04-06
NL300232I1 (nl) 2006-09-01
ATE322280T1 (de) 2006-04-15
EP1115417B1 (en) 2006-04-05
IS8807A (is) 2009-03-10
PT1674107T (pt) 2016-12-07
PT1115417E (pt) 2006-07-31
HK1040363A1 (en) 2002-06-07
US6468967B1 (en) 2002-10-22

Similar Documents

Publication Publication Date Title
ES2259845T3 (es) Uso de la daptomicina.
Raja et al. Daptomycin
Rybak The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram‐positive bacteria
Chambers In vitro and in vivo antistaphylococcal activities of L-695,256, a carbapenem with high affinity for the penicillin-binding protein PBP 2a
Chahine et al. Tedizolid: a new oxazolidinone antibiotic for skin and soft tissue infections
Lin et al. Dalbavancin: a new option for the treatment of gram-positive infections
RU2232592C2 (ru) Способ лечения бактериальной инфекции
US6465428B1 (en) Pharmaceutical combinations based on dalfopristine and quinupristine, and on cefepime
HK1094672A (en) Use of daptomycin
CZ20011014A3 (cs) Farmaceutické přípravky obsahující lipoproteinová antibiotika
CN107847501A (zh) 抗菌组合物以及方法
Dharshini PHARMACOECONOMIC EVALUATION OF VANCOMYCIN AND TEICOPLANIN
AU2001284095B2 (en) Combinations of dalfopristine/quinupristine with cefpirome
Sun et al. Daptomycin
Shankar et al. Newer antibiotics
Jacqueline et al. Antibiotics Against Endocarditis–Past, Present and Future (Experimental Data)
Marriott Meeting Highlights: Anti-infectives: The 1st European Congress of Antimicrobial Chemotherapy
BR112017014670B1 (pt) Derivado de polimixina e usos do mesmo
HK1207868B (en) Combinations with a backbone-cyclized peptide